Medical test kit maker Meridian Bioscience Inc. said Wednesday it signed a royalty-based development and distribution deal with DiaSorin S.p.A.
Under the deal, DiaSorin will use key Meridian technology to develop several infectious disease products for use on their Liaison automated detection systems. The deal will give Meridian royalties based on the type of test and specific geographic market.
DiaSorin, based in Italy, will have exclusive distribution rights for the developed products in every geographic market except the United States and United Kingdom, where Meridian will keep the option.
The first two products to be developed will be aimed at the detection of Clostridium difficile, a hospital-acquired infection, and Helicobacter pylori, a cause of stomach ulcers.
Shares of Meridian rose 13 cents to $16.92 in morning trading.